GMED reported first-quarter 2025 adjusted earnings per share (EPS) of 68 cents, which missed the Zacks Consensus Estimate by ...

Despite revenue challenges, Globus Medical Inc (GMED) reports significant free cash flow growth and strategic acquisitions to ...

Globus Medical stock is down today on an unexpectedly soft Q1 amid an earlier-than-planned integration with recently acquired ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research ...

In trading on Friday, shares of Globus Medical Inc (Symbol: GMED) entered into oversold territory, hitting an RSI reading of 23.1, after changing hands as low as $54.75 per share. By comparison ...

BTIG analyst Ryan Zimmerman lowered the firm’s price target on Globus Medical (GMED) to $77 from $88 and keeps a Buy rating on the shares. The ...

Globus Medical, Inc.’s GMED share price has dipped by 21.03%, which has investors questioning if this is right time to buy.

Across the recent three months, 6 analysts have shared their insights on Globus Medical GMED, expressing a variety of opinions spanning from bullish to bearish. Summarizing their recent ...

Detailed price information for Globus Medical Inc (GMED-N) from The Globe and Mail including charting and trades.

For the quarter ended March 2025, Globus Medical (GMED) reported revenue of $598.12 million, down 1.4% over the same period last year. EPS came in at $0.68, compared to $0.72 in the year-ago quarter.